189 reports of this reaction
1.5% of all ICATIBANT ACETATE reports
#11 most reported adverse reaction
COVID 19 is the #11 most commonly reported adverse reaction for ICATIBANT ACETATE, manufactured by Takeda Pharmaceuticals America, Inc.. There are 189 FDA adverse event reports linking ICATIBANT ACETATE to COVID 19. This represents approximately 1.5% of all 12,796 adverse event reports for this drug.
Patients taking ICATIBANT ACETATE who experience covid 19 should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COVID 19 is a less commonly reported adverse event for ICATIBANT ACETATE, but still significant enough to appear in the safety profile.
In addition to covid 19, the following adverse reactions have been reported for ICATIBANT ACETATE:
The following drugs have also been linked to covid 19 in FDA adverse event reports:
COVID 19 has been reported as an adverse event in 189 FDA reports for ICATIBANT ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
COVID 19 accounts for approximately 1.5% of all adverse event reports for ICATIBANT ACETATE, making it a notable side effect.
If you experience covid 19 while taking ICATIBANT ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.